

**Supplementary Table SI.** Summary characteristics of the study group in relation to the period of illness

Variable	Omicron N = 81 <sup>1</sup>	Pre-Omicron, N = 1,069 <sup>1</sup>	P-value <sup>2</sup>
Age	55.43 (13.16)	52.43 (13.17)	0.053
Female	57/81 (70%)	694/1,069 (65%)	0.32
BMI [kg/m <sup>2</sup> ]	28.32 (5.69)	27.67 (5.30)	0.43
Underweight	0/81 (0%)	7/1,069 (1%)	> 0.9
Healthy weight	22/81 (27%)	336 (31%)	0.4
Overweight	32 (40%)	404 (38%)	0.8
Obesity	27/81 (33%)	322 (30%)	0.5
Comorbidities:			
Hypertension	32/81 (40%)	397/1,069 (37%)	0.67
Diabetes	10/81 (12%)	84/1,069 (8%)	0.16
Coronary artery disease	4/81 (5%)	51/1,069 (5%)	0.79
Myocardial infarction	3/81 (4%)	18/1,069 (2%)	0.18
Heart failure	0/81 (0%)	6/1,069 (1%)	> 0.99
Hyperlipidaemia	21/81 (26%)	223/1,069 (21%)	0.28
Respiratory diseases	7/81 (9%)	121/1,069 (11%)	0.46
Vaccination against COVID-19	79/81 (98%)	922/1,069 (86%)	0.004
Place of isolation:			
Home isolation	76/81 (94%)	933/1,069 (87%)	0.083
Hospitalisation	5/81 (6%)	136/1,069 (13%)	0.087
Temperature < 36.6°C	10/81 (12%)	160/1,069 (15%)	0.52
Fever or chills	52/81 (64%)	752/1,069 (70%)	0.24
Cough	66/81 (81%)	736/1,069 (69%)	0.017
Dyspnoea	44/81 (54%)	531/1,069 (50%)	0.42
Isolated anosmia	6/81 (7.4%)	115/1,069 (11%)	0.34
Isolated ageusia	3/81 (3.7%)	70/1,069 (6.5%)	0.31
Anosmia or ageusia	1/81 (1.2%)	488/1,069 (46%)	< 0.001
Impaired hearing	12/81 (15%)	109/1,069 (10%)	0.19
Significant fatigue	56/81 (69%)	831/1,069 (78%)	0.076
Chest pain	38/81 (47%)	492/1,069 (46%)	0.88
Arthralgia	61/81 (75%)	777/1,069 (73%)	0.61
Headache	53/81 (65%)	661/1,069 (62%)	0.52
Diarrhoea or vomiting	22/81 (27%)	275/1,069 (26%)	0.78
BP elevation or dysregulation of previously well-controlled BP	17/81 (21%)	161/1,069 (15%)	0.16
Duration of symptoms [days]	7.00 (5.00, 14.00)	10.00 (7.00, 14.00)	< 0.001
Sum of symptoms	8.00 (6.00, 11.00)	8.00 (6.00, 11.00)	0.69

<sup>1</sup>Mean (SD) or median [25–75%]; n/N (%); <sup>2</sup>Wilcoxon rank sum test; Pearson's  $\chi^2$  test; Fisher's exact test.